NASOPHARANGEAL CANCER

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This Phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen (gemcitabine and cisplatin) plus the immunotherapy drug toripalimab can help control recurrent or metastatic nasopharyngeal carcinoma. About 55 adults aged 18-65 with confirmed n…

This study tests whether adding an immunotherapy drug (penpulimab) to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than the usual maintenance drug capecitabine for people with high-risk nasopharyngeal cancer. About 142 participants with…

This study is for people whose nasopharyngeal cancer has come back after initial treatment and cannot be removed by surgery. Participants first receive a combination of chemotherapy and an immunotherapy drug (PD-1 inhibitor). Those whose tumors shrink or disappear are then random…

This phase 3 trial is testing whether giving radiation only when needed (salvage therapy) works as well as giving it right away after immunotherapy and chemotherapy in people with nasopharyngeal cancer that has spread. The goal is to see if delaying radiation can reduce side effe…

This study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …